Longeveron Inc. (LGVN) released its 2025 full‑year financial results on March 17, 2026, after market close. The company posted total revenue of $1.2 million, a 50% decline from $2.4 million in 2024, driven by a drop in contract‑manufacturing revenue and reduced clinical‑trial participation. Net loss widened to $22.7 million, up 41% from 2024, largely due to higher personnel, contract‑manufacturing‑and‑development (CMC), and severance expenses.
The company’s non‑GAAP earnings per share (EPS) for the year was –$0.22, a narrower loss than the consensus estimate of –$0.42. The EPS beat was driven by disciplined cost management that offset the revenue decline, while the company’s cash position of $4.7 million is expected to fund operations into the third quarter of 2026 following a private placement of approximately $15.9 million.
Management highlighted that the company remains on track for third‑quarter 2026 top‑line results from its pivotal Phase 2b HLHS trial (ELPIS II). The FDA has confirmed ELPIS II as a pivotal study, positioning Longeveron to file a biologics license application (BLA) for HLHS in 2026. The company also noted that its cash reserves should support operations through Q4 2026, providing a buffer amid the current revenue contraction.
Analysts noted that while revenue fell sharply, the company beat both revenue and EPS estimates. Revenue beat of $0.22 million (145% above the $0.15 million consensus) and an EPS beat of $0.20 (48% better than the –$0.42 estimate) underscored effective cost control and a focus on high‑margin clinical‑trial services. The muted after‑hours reaction—down roughly 1%—was attributed to a consolidation following a 65% run‑up in the past month, rather than a fundamental shift in the company’s outlook.
Looking ahead, Longeveron has not issued new guidance for 2026, but the company’s emphasis on the HLHS BLA filing and continued investment in its cellular‑therapy pipeline signals confidence in long‑term growth. The company’s cash runway and ongoing private‑placement proceeds provide a cushion as it navigates the current revenue downturn while pursuing regulatory milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.